Mar 30,2023

Bigfoot Biomedical acquires insulin titration algorithm developed at McGill University

Bigfoot Biomedical announced today that it acquired a reinforcement learning algorithm for insulin titration from McGill University. Developers at McGill designed the algorithm to observe how well people with insulin-requiring diabetes respond to a particular dose. It provides a recommended adjustment based on the body’s response. Less than two years ago, Bigfoot Biomedical launched its Bigfoot Unity platform in some U.S. states. Last year, Brewer called it a “transformational attempt” to simplify CGMs and the data they produce to tell people how much insulin to take at a given point in time. Just last month, the company made another play to further enhance this platform. Bigfoot sold pump-based automated insulin delivery technology patents to pump maker Insulet for $25 million. This asset sale generated significant funds to expand the Bigfoot Unity diabetes management system. The company said it aims to expand access by offering Bigfoot Unity through the pharmacy channel later this year.

PRODUCT

#insulin pen

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 29,2023

11 diabetes tech startups you need to know from the 16th ATTD Conference

At The 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), there were a number of startups featured in the “Tech Fair,” demonstrating what they have to offer. In total, 14 promising startups received ATTD startup grants. such as DiabetesWise, Diatech Diabetes, GluCare, Ryse Health, Glaice among others.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Mar 29,2023

This implantable fuel cell generates electricity from glucose

A team of researchers developed an implantable fuel cell that uses excess glucose from tissue to generate electrical energy. By combining the fuel cell with artificial data cells, the team produced insulin with the touch of a button. This effectively lowered blood glucose levels like the natural process in the pancreas. Given that current treatments for diabetes often include insulin pumps that require a reliable energy supply, the team feels it may have found a new way to produce that energy.

CLINICAL STUDY

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Mar 29,2023

Astellas and Roche Diabetes Care Japan Ink Partnership Agreement to Develop and Commercialize Integrated Diabetes Self-management Solution with BlueStar®

Astellas Pharma Inc. announced that it has entered into an agreement with Roche Diabetes Care Japan Co., Ltd. for the development and commercialization of Roche Diabetes Care’s Accu-Chek®Guide Me blood glucose monitoring system as a combined medical product with BlueStar®. BlueStar is an FDA-cleared digital health solution for diabetes patients, developed by Welldoc, Inc. and is currently marketed in the U.S. and Canada. Astellas and Welldoc are jointly developing BlueStar in Japan. The combined medical product solution, which is being developed in Japan, is expected to support patients with managing their diabetes by capturing, storing, and transmitting blood glucose data which is obtained from Roche Diabetes Care’s Accu-Chek® Guide Me system and track medication, diet, activity and exercise in Welldoc’s BlueStar(app).

COLLABORATION PARTNERSHIP

#r&d

#bgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 29,2023

Amazon Pharmacy adds feature to automatically include manufacturer coupons

Amazon Pharmacy is partnering with a slew of pharma companies to offer a new feature that automatically applies manufacturer-sponsored coupons to a patient's medication order when eligible. The tech giant's online pharmacy said it's working with GSK, Kaléo, Novo Nordisk and Dexcom to integrate coupons for their brand-name drugs, including sensors and transmitters for Dexcom's G6 and G7 continuous glucose monitors.

View Analyst & Ambassador Comments
Go to original news
Mar 29,2023

ABBOTT HOSTS CONFERENCE CALL FOR FIRST-QUARTER EARNINGS

Abbott will announce its first-quarter 2023 financial results on Wednesday, April 19, 2023, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern), and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Mar 27,2023

MicroTech Medical Inc Announced the Annual Results

For the year ended December 31, 2022, MicroTech Medical recorded revenue of RMB173.54 million, representing an increase of 14.6% from RMB151.40 million for the year ended December 31, 2021. The increase was mainly attributable to the commercialization of AiDEX CGMS; the continuing growth in domestic terminal implantations of insulin pumps; and the steady growth in revenue from international sale of BGMS products.

View Analyst & Ambassador Comments
Go to original news
Mar 27,2023

Better Therapeutics to cut 35% of workforce

Better Therapeutics announced that it commenced a workforce reduction of approximately 35% of its employees. CEO Frank Karbe sent an email to Better Therapeutics employees on March 23, announcing the workforce reduction. In it, Karbe wrote that the company is implementing cost-saving actions to further extend its financial runway ahead of “critical milestones.” Those include, over the next few months, potential FDA marketing authorization and a subsequent launch for BT-001. BT-001 is a digital therapeutic for treating type 2 diabetes.

View Analyst & Ambassador Comments
Go to original news
Mar 27,2023

Philips unveils new Virtual Care Management portfolio

Philips announced today that it debuted its Philips Virtual Care Management portfolio of flexible solutions and services. The Amsterdam-based medtech giant aims to help health systems, providers, payers and employers connect with patients from virtually anywhere. It designed the portfolio to reduce pressure on hospital staff by decreasing emergency department visits and reducing care costs by better managing chronic care. Philips Virtual Care Management’s condition-specific protocols now include diabetes, hypertension, chronic kidney disease, chronic obstructive pulmonary disease (COPD) and heart disease. These protocols combine with connected devices and engagement tools on a secure, interoperable cloud-based platform. Licensed clinical professionals offer monitoring and personalized coaching, while Philips brings expert-led professional services. Philips said its virtual care program “goes beyond traditional remote patient management.” It features scalable solutions and services to foster patient engagement and empower healthier behaviors.

PRODUCT

#virtual care

#rpm

View Analyst & Ambassador Comments
Go to original news
Mar 27,2023

Canada Diabetes Market Analysis, Size, & Forecasts Report 2023: A $1.53 Billion Market by 2028

Canada's Diabetes Market will reach US$ 1.53 Billion by 2028 with a CAGR of 3.85% during the forecast period (2023-2028). The only drawback that might affect the Canadian diabetes industry growth is the high cost of insulin pens, according to the publisher. Canadian diabetes market was valued at US$ 1.22 Billion in 2022.

#cgm

#bgm

#insulin pen

View Analyst & Ambassador Comments
Go to original news